Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D09SZG
|
|||
Former ID |
DNC002591
|
|||
Drug Name |
[2(R,S)-2-Sulfanylheptanoyl]-Phe-Ala
|
|||
Synonyms |
[2(R,S)-2-Sulfanylheptanoyl]-phe-ala; [2(R,S)-2-SULFANYLHEPTANOYL]-PHE-ALA; TI1; AC1NRDCJ; 1qf1; DB02597; N-[(2S)-2-sulfanylheptanoyl]-L-phenylalanyl-L-alanine; N-[N-[(S)-2-Mercaptoheptanoyl]-L-phenylalanyl]-L-alanine; (2S)-2-[[(2S)-3-phenyl-2-[[(2S)-2-sulfanylheptanoyl]amino]propanoyl]amino]propanoic acid; (2S)-2-[(2S)-3-phenyl-2-[(2S)-2-sulfanylheptanamido]propanamido]propanoic
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1], [2] | |
Structure |
Download2D MOL |
|||
Formula |
C19H28N2O4S
|
|||
Canonical SMILES |
CCCCCC(C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C)C(=O)O)S
|
|||
InChI |
1S/C19H28N2O4S/c1-3-4-6-11-16(26)18(23)21-15(12-14-9-7-5-8-10-14)17(22)20-13(2)19(24)25/h5,7-10,13,15-16,26H,3-4,6,11-12H2,1-2H3,(H,20,22)(H,21,23)(H,24,25)/t13-,15-,16-/m0/s1
|
|||
InChIKey |
GOIYKVXXGCPHQU-BPUTZDHNSA-N
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Neutral endopeptidase (MME) | Target Info | Inhibitor | [2] |
Poly [ADP-ribose] polymerase 1 (PARP1) | Target Info | Inhibitor | [1] | |
KEGG Pathway | Renin-angiotensin system | |||
Hematopoietic cell lineage | ||||
Protein digestion and absorption | ||||
Alzheimer's disease | ||||
Base excision repair | ||||
NF-kappa B signaling pathway | ||||
NetPath Pathway | EGFR1 Signaling Pathway | |||
TGF_beta_Receptor Signaling Pathway | ||||
Panther Pathway | FAS signaling pathway | |||
Pathway Interaction Database | Integrin-linked kinase signaling | |||
Caspase Cascade in Apoptosis | ||||
Notch-mediated HES/HEY network | ||||
Reactome | Metabolism of Angiotensinogen to Angiotensins | |||
Dual Incision in GG-NER | ||||
WikiPathways | Metabolism of Angiotensinogen to Angiotensins | |||
Primary Focal Segmental Glomerulosclerosis FSGS | ||||
Alzheimers Disease | ||||
FAS pathway and Stress induction of HSP regulation | ||||
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | ||||
Nanoparticle triggered regulated necrosis | ||||
Corticotropin-releasing hormone |
References | Top | |||
---|---|---|---|---|
REF 1 | Identification of potent nontoxic poly(ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res. 2003 Jul;9(7):2711-8. | |||
REF 2 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.